Comparison of alendronate and teriparatide for the bone mineral density around implant after total hip arthroplasty

Comparison of alendronate and teriparatide for the bone mineral density around implant after total hip arthroplasty - RCT for BMD loss after THA teriparatide vs alendronate

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016158

Enrollment

Registered

2015-01-09

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cases after primary total hip arthroplasty

Interventions

teriparatide daily administration (Forteo 20 ug, Eli Lilly Japan K.K.) beginning on postoperative week 2 and continuing until week 48 weekly administration of alendronate (Bonalon 35 mg, Teijin Pharma

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Primary total hip arthroplasty cases applicable for standardized implant under informed consent

Exclusion criteria

Exclusion criteria: cases of malignant tumor cases with difficulty of one year follow-up

Design outcomes

Primary

Measure	Time frame
Change of bone mineral density in teriparatide treatment, alendronate treatment, and control group	—

Secondary

Measure	Time frame
Change of bone formation markers in teriparatide treatment, alendronate treatment, and control group	—

Countries

Japan

Contacts

Public ContactNaomi Kobayashi

Yokohama City University Orthopaedic surgery

naomik58@aol.com045-787-2655

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026